What We're Reading: Page 142
Industry reads hand-picked by our editors
Nov 02, 2021
-
The New York Times
How Often Do Covid Vaccines Cause Heart Problems in Kids?
-
Financial Times
Progressive Democrats scramble to secure curbs on drug prices
-
Chemical & Engineering News
On the hunt for monomeric degraders
-
STAT
The Purdue bankruptcy plan was approved. Where is the money?
Nov 01, 2021
-
The Atlantic
Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose?
-
Bloomberg
China-Focused Biotech LianBio Raises $325 Million in U.S. IPO
-
The Washington Post
Dems see progress in adding drug cost curbs to budget bill
-
Genetic Engineering & Biotechnology News
Neuropsychiatric Drug Developers Show a Renewed Sense of Purpose
Oct 29, 2021
-
Science
2021’s Top Employers engage, nurture, and harness the power of scientists
-
Politico
‘Bereft’: How Operation Warp Speed’s decisions left the world waiting for a vaccine
-
Business Insider
Regeneron's top scientist George Yancopoulos tells us the one big thing he thinks gene-editing biotechs are doing wrong
-
Fierce Biotech
Frazier has raised an $830M public life science fund. Here's how it plans to invest the cash
Oct 28, 2021
-
Science
The pandemic turned them into celebrities. Now scientists are grappling with new power—and internet hate
-
BioCentury
How Woodcock has changed FDA
-
The New York Times
A cheap antidepressant lowers the risk of Covid hospitalization, a large study finds.
-
The Boston Globe
As labs replace offices across Greater Boston, pushback is mounting from wary neighbors
Oct 27, 2021
-
Associated Press
Africa tries to end vaccine inequity by replicating its own
-
Bloomberg
Glaxo Appoints Top Scientist to Board Ahead of Company Split
-
The New York Times
This May Be Democrats’ Best Chance to Lower Drug Prices
-
Reuters
Novavax files for COVID-19 vaccine's UK authorization
Previous
